Photographer: Daniel Acker/Bloomberg

Mylan’s Stock Jumps After $465 Million EpiPen Settlement

  • Shares rise as much as 13%, rebound from three-year low
  • Company also gets inquiry from SEC asking about Medicaid

Mylan NV climbed as much as 13 percent after the drugmaker agreed to pay the U.S. government $465 million in a swift settlement over how it charged Medicaid for its allergy shot EpiPen.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.